Stoke Therapeutics (NASDAQ:STOK) Earns Buy Rating from Chardan Capital

Stoke Therapeutics (NASDAQ:STOK)‘s stock had its “buy” rating reaffirmed by analysts at Chardan Capital in a research note issued on Wednesday,Benzinga reports. They presently have a $24.00 price target on the stock. Chardan Capital’s target price would suggest a potential upside of 188.12% from the company’s previous close.

A number of other brokerages have also commented on STOK. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a report on Tuesday. HC Wainwright upped their target price on shares of Stoke Therapeutics from $35.00 to $47.00 and gave the company a “buy” rating in a research note on Tuesday, February 18th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Stoke Therapeutics presently has an average rating of “Buy” and a consensus price target of $23.00.

Stoke Therapeutics Trading Up 0.8 %

Shares of Stoke Therapeutics stock opened at $8.33 on Wednesday. The company has a fifty day moving average price of $9.49 and a 200 day moving average price of $11.49. Stoke Therapeutics has a twelve month low of $5.80 and a twelve month high of $17.58. The stock has a market cap of $441.22 million, a price-to-earnings ratio of -3.97 and a beta of 0.99.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings results on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The firm had revenue of $22.61 million during the quarter, compared to analysts’ expectations of $4.20 million. Analysts forecast that Stoke Therapeutics will post -2.01 earnings per share for the current year.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, Director Edward M. Md Kaye sold 10,382 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $90,011.94. Following the completion of the transaction, the director now directly owns 148,253 shares in the company, valued at $1,285,353.51. The trade was a 6.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Barry Ticho sold 3,884 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $33,674.28. Following the completion of the transaction, the insider now owns 63,962 shares of the company’s stock, valued at approximately $554,550.54. The trade was a 5.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 16,532 shares of company stock worth $143,332 over the last ninety days. Company insiders own 11.30% of the company’s stock.

Institutional Investors Weigh In On Stoke Therapeutics

A number of hedge funds have recently made changes to their positions in STOK. Intech Investment Management LLC bought a new stake in shares of Stoke Therapeutics during the third quarter valued at approximately $160,000. Charles Schwab Investment Management Inc. lifted its stake in shares of Stoke Therapeutics by 9.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 316,134 shares of the company’s stock worth $3,885,000 after acquiring an additional 26,870 shares during the period. BNP Paribas Financial Markets lifted its stake in shares of Stoke Therapeutics by 1,589.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 76,154 shares of the company’s stock worth $936,000 after acquiring an additional 71,647 shares during the period. Checkpoint Capital L.P. acquired a new stake in shares of Stoke Therapeutics in the 3rd quarter worth approximately $1,936,000. Finally, RTW Investments LP lifted its stake in shares of Stoke Therapeutics by 10.1% in the 3rd quarter. RTW Investments LP now owns 4,652,285 shares of the company’s stock worth $57,177,000 after acquiring an additional 427,447 shares during the period.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.